, Graphique 5.4. La prévalence des troubles mentaux est plus élevée chez les jeunes que dans l?ensemble de la population, La description des résultats du repas test chez les patients PTDM est résumée dans

M. Marre, Présentation de la traduction par la Société Francophone du Diabète de la prise de position émise par l?Association Américaine du Diabète (ADA) et l?Association Européenne pour l?Étude du Diabète (EASD) sur la prise en charge de l?hyperglycémie chez les patients diabétiques de type 2 : une stratégie centrée sur le patient, Médecine des Maladies Métaboliques, vol.6, pp.I-II, 2012.

J. Davidson, A. Wilkinson, J. Dantal, F. Dotta, H. Haller et al., NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1, Transplantation, vol.75, issue.Supplement, pp.SS3-SS24, 2003.

A. Sharif, M. Hecking, A. P. De-vries, E. Porrini, M. Hornum et al., Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions, American Journal of Transplantation, vol.14, issue.9, pp.1992-2000, 2014.

, 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes?2019, Diabetes Care, vol.42, issue.Supplement 1, pp.S13-S28, 2018.

A. Sharif and K. Baboolal, Diagnostic Application of the A1c Assay in Renal Disease, Journal of the American Society of Nephrology, vol.21, issue.3, pp.383-385, 2010.

A. Sharif, R. H. Moore, and K. Baboolal, The Use of Oral Glucose Tolerance Tests to Risk Stratify for New-Onset Diabetes After Transplantation: An Underdiagnosed Phenomenon, Transplantation, vol.82, issue.12, pp.1667-1672, 2006.

T. G. Valderhaug, T. Jenssen, A. Hartmann, K. Midtvedt, H. Holdaas et al., Fasting Plasma Glucose and Glycosylated Hemoglobin in the Screening for Diabetes Mellitus After Renal Transplantation, Transplantation, vol.88, issue.3, pp.429-434, 2009.

S. Shabir, S. Jham, L. Harper, S. Ball, R. Borrows et al., Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation, Transplant International, vol.26, issue.3, pp.315-321, 2013.

A. M. Ussif, A. Åsberg, T. A. Halden, E. Nordheim, A. Hartmann et al., Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation, BMC Nephrology, vol.20, issue.1, p.12, 2019.

C. J. Yates, S. Fourlanos, P. G. Colman, and S. J. Cohney, Screening for New-Onset Diabetes After Kidney Transplantation, Transplantation Journal, vol.96, issue.8, pp.726-731, 2013.

D. Dubois-laforgue, Diabètes post-transplantation rénale, Néphrologie & Thérapeutique, vol.13, issue.1, pp.S137-S146, 2017.

K. M. Dungan, S. S. Braithwaite, and J. Preiser, Stress hyperglycaemia, The Lancet, vol.373, issue.9677, pp.1798-1807, 2009.

H. A. Chakkera, E. J. Weil, J. Castro, R. L. Heilman, K. S. Reddy et al., Hyperglycemia during the Immediate Period after Kidney Transplantation, Clinical Journal of the American Society of Nephrology, vol.4, issue.4, pp.853-859, 2009.

E. L. Porrini, J. M. Díaz, F. Moreso, P. I. Delgado-mallén, I. Silva-torres et al., Clinical evolution of post-transplant diabetes mellitus, Nephrology Dialysis Transplantation, vol.31, issue.3, pp.495-505, 2015.

K. Y. Hur, M. S. Kim, Y. S. Kim, E. S. Kang, J. H. Nam et al., Risk Factors Associated With the Onset and Progression of Posttransplantation Diabetes in Renal Allograft Recipients, Diabetes Care, vol.30, issue.3, pp.609-615, 2007.

B. El-essawy and F. Kandeel, Pre, peri and posttransplant diabetes mellitus, Current Opinion in Nephrology and Hypertension, vol.28, issue.1, pp.47-57, 2019.

A. M. Miles, N. Sumrani, R. Horowitz, P. Homel, V. Maursky et al., DIABETES MELLITUS AFTER RENAL TRANSPLANTATION, Transplantation, vol.65, issue.3, pp.380-384, 1998.

N. Joss, C. E. Staatz, A. H. Thomson, and A. G. Jardine, Predictors of new onset diabetes after renal transplantation, Clinical Transplantation, vol.21, issue.1, pp.136-143, 2007.

K. Y. Hur, M. S. Kim, Y. S. Kim, E. S. Kang, J. H. Nam et al., Risk Factors Associated With the Onset and Progression of Posttransplantation Diabetes in Renal Allograft Recipients, Diabetes Care, vol.30, issue.3, pp.609-615, 2007.

H. A. Chakkera, R. L. Hanson, S. M. Raza, J. K. Distefano, M. P. Millis et al., Pilot Study: Association of Traditional and Genetic Risk Factors and New-Onset Diabetes Mellitus Following Kidney Transplantation, Transplantation Proceedings, vol.41, issue.10, pp.4172-4177, 2009.

B. L. Kasiske, J. J. Snyder, D. Gilbertson, and A. J. Matas, Diabetes Mellitus after Kidney Transplantation in the United States, American Journal of Transplantation, vol.3, issue.2, pp.178-185, 2003.

J. Peracha, J. Nath, A. Ready, S. Tahir, K. Parekh et al., Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients, Transplant International, vol.29, issue.6, pp.727-739, 2016.

R. A. Hamer, C. L. Chow, A. C. Ong, and W. S. Mckane, Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation, Transplantation, vol.83, issue.1, pp.36-40, 2007.

K. Vareesangthip, P. Tong, R. Wilkinson, and T. H. Thomas, Insulin resistance in adult polycystic kidney disease, Kidney International, vol.52, issue.2, pp.503-508, 1997.

I. Ruderman, R. Masterson, C. Yates, A. Gorelik, S. J. Cohney et al., New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: A retrospective cohort study, Nephrology, vol.17, issue.1, pp.89-96, 2011.

K. Madziarska, W. Weyde, M. Krajewska, D. Patrzalek, D. Janczak et al., The increased risk of post-transplant diabetes mellitus in peritoneal dialysis-treated kidney allograft recipients, Nephrology Dialysis Transplantation, vol.26, issue.4, pp.1396-1401, 2010.

B. Bayés, M. L. Granada, M. C. Pastor, R. Lauzurica, I. Salinas et al., Obesity, Adiponectin and Inflammation as Predictors of New-Onset Diabetes Mellitus After Kidney Transplantation, American Journal of Transplantation, vol.7, issue.2, pp.416-422, 2007.

C. P. Johnson, S. Gallagher-lepak, Y. Zhu, C. Porth, S. Kelber et al., FACTORS INFLUENCING WEIGHT GAIN AFTER RENAL TRANSPLANTATION, Transplantation, vol.56, issue.4, pp.822-826, 1993.

S. Caillard, L. Eprinchard, P. Perrin, L. Braun, F. Heibel et al., Incidence and Risk Factors of Glucose Metabolism Disorders in Kidney Transplant Recipients: Role of Systematic Screening by Oral Glucose Tolerance Test, Transplantation, vol.91, p.1, 2011.

E. Porrini, P. Delgado, C. Bigo, A. Alvarez, M. Cobo et al., Impact of Metabolic Syndrome on Graft Function and Survival After Cadaveric Renal Transplantation, American Journal of Kidney Diseases, vol.48, issue.1, pp.134-142, 2006.

F. L. Luan, E. Langewisch, and A. Ojo, Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients, Clinical Transplantation, vol.24, issue.6, pp.778-783, 2010.

F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, F. Kanwal et al., Post-Transplant Diabetes Mellitus and HCV Seropositive Status After Renal Transplantation: Meta-Analysis of Clinical Studies, American Journal of Transplantation, vol.5, issue.10, pp.2433-2440, 2005.

M. Seirafi and F. Negro, Hepatitis C and insulin resistance, Rev Med Suisse, vol.4, pp.1859-1862, 2008.

R. D. Bloom, Association of Hepatitis C with Posttransplant Diabetes in Renal Transplant Patients on Tacrolimus, Journal of the American Society of Nephrology, vol.13, issue.5, pp.1374-1380, 2002.

J. Hjelmes?th, S. Sagedal, A. Hartmann, H. Rollag, T. Egeland et al., Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation, Diabetologia, vol.47, issue.9, pp.1550-1556, 2004.

B. Einollahi, M. Motalebi, M. Salesi, M. Ebrahimi, and M. Taghipour, The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings, J Nephropathol, vol.3, pp.139-148, 2014.

S. Gourishankar, G. S. Jhangri, M. Tonelli, L. H. Wales, and S. M. Cockfield, Development of Diabetes Mellitus Following Kidney Transplantation: A Canadian Experience, American Journal of Transplantation, vol.4, issue.11, pp.1876-1882, 2004.

D. K. De-vries, J. H. Lindeman, J. Ringers, M. E. Reinders, T. J. Rabelink et al., Donor Brain Death Predisposes Human Kidney Grafts to a Proinflammatory Reaction after Transplantation, American Journal of Transplantation, vol.11, issue.5, pp.1064-1070, 2011.

S. Afzal, S. E. Bojesen, and B. G. Nordestgaard, Low 25-Hydroxyvitamin D and Risk of Type 2 Diabetes: A Prospective Cohort Study and Metaanalysis, Clinical Chemistry, vol.59, issue.2, pp.381-391, 2013.

L. Fur and A. , Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation, Transpl. Int, vol.29, pp.207-215, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02153305

J. W. Huang, O. Famure, Y. Li, and S. J. Kim, Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation, Journal of the American Society of Nephrology, vol.27, issue.6, pp.1793-1800, 2015.

S. Van-laecke, W. Van-biesen, F. Verbeke, D. De-bacquer, P. Peeters et al., Posttransplantation Hypomagnesemia and Its Relation with Immunosuppression as Predictors of New-Onset Diabetes after Transplantation, American Journal of Transplantation, vol.9, issue.9, pp.2140-2149, 2009.

A. Garnier, A. Duveau, M. Planchais, J. Subra, J. Sayegh et al., Serum Magnesium after Kidney Transplantation: A Systematic Review, Nutrients, vol.10, issue.6, p.729, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01815356

M. Rodriguez-moran and F. Guerrero-romero, Oral Magnesium Supplementation Improves Insulin Sensitivity and Metabolic Control in Type 2 Diabetic Subjects: A randomized double-blind controlled trial, Diabetes Care, vol.26, issue.4, pp.1147-1152, 2003.

S. Van-laecke, E. V. Nagler, Y. Taes, W. Van-biesen, P. Peeters et al., The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial, Transplant International, vol.27, issue.9, pp.895-902, 2014.

E. S. Kang, M. S. Kim, Y. S. Kim, K. Y. Hur, S. J. Han et al., A Variant of the Transcription Factor 7-Like 2 (TCF7L2) Gene and the Risk of Posttransplantation Diabetes Mellitus in Renal Allograft Recipients, Diabetes Care, vol.31, issue.1, pp.63-68, 2007.

E. S. Kang, M. S. Kim, Y. S. Kim, C. H. Kim, S. J. Han et al., A Polymorphism in the Zinc Transporter Gene SLC30A8 Confers Resistance Against Posttransplantation Diabetes Mellitus in Renal Allograft Recipients, Diabetes, vol.57, issue.4, pp.1043-1047, 2007.

J. Zuber, C. Bellanné-chantelot, C. Carette, G. Canaud, S. Gobrecht et al., HNF1B-related diabetes triggered by renal transplantation, Nature Reviews Nephrology, vol.5, issue.8, pp.480-484, 2009.

S. Kanda, N. Morisada, N. Kaneko, T. Yabuuchi, Y. Nawashiro et al., New-onset diabetes after renal transplantation in a patient with a novelHNF1Bmutation, Pediatric Transplantation, vol.20, issue.3, pp.467-471, 2016.

J. Yang, I. I. Hutchinson, T. Shah, and D. I. Min, Genetic and Clinical Risk Factors of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients, Transplantation, vol.91, issue.10, pp.1114-1119, 2011.

J. A. Mccaughan, A. J. Mcknight, and A. P. Maxwell, Genetics of New-Onset Diabetes after Transplantation, Journal of the American Society of Nephrology, vol.25, issue.5, pp.1037-1049, 2013.

J. Bamoulid, C. Courivaud, M. Deschamps, P. Mercier, C. Ferrand et al., IL-6 Promoter Polymorphism ?174 Is Associated with New-Onset Diabetes after Transplantation, Journal of the American Society of Nephrology, vol.17, issue.8, pp.2333-2340, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00469512

Y. G. Kim, C. Ihm, T. W. Lee, S. H. Lee, K. H. Jeong et al., Association of Genetic Polymorphisms of Interleukins With New-Onset Diabetes After Transplantation in Renal Transplantation, Transplantation Journal, vol.93, issue.9, pp.900-907, 2012.

K. Numakura, S. Satoh, N. Tsuchiya, Y. Horikawa, T. Inoue et al., Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplant Recipients Treated with Tacrolimus, Transplantation, vol.80, issue.10, pp.1419-1424, 2005.

B. B. Nicoletto, G. C. Souza, N. K. Fonseca, A. Centenaro, R. C. Manfro et al., Association Between 276G/T Adiponectin Gene Polymorphism and New-Onset Diabetes After Kidney Transplantation, Transplantation Journal, vol.96, issue.12, pp.1059-1064, 2013.

H. Schäcke, W. D. Döcke, and K. Asadullah, Mechanisms involved in the side effects of glucocorticoids, Pharmacology & Therapeutics, vol.96, issue.1, pp.23-43, 2002.

J. M. Boots, M. H. Christiaans, E. M. Van-duijnhoven, R. Van-suylen, and J. P. Van-hooff, Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study, Transplantation Proceedings, vol.34, issue.5, pp.1698-1699, 2002.

E. S. Woodle, M. R. First, J. Pirsch, F. Shihab, A. O. Gaber et al., A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy, Transactions of the ... Meeting of the American Surgical Association, vol.126, pp.205-220, 2008.

K. Midtvedt, Insulin Resistance after Renal Transplantation: The Effect of Steroid Dose Reduction and Withdrawal, Journal of the American Society of Nephrology, vol.15, issue.12, pp.3233-3239, 2004.

C. B. Drachenberg, D. K. Klassen, M. R. Weir, A. Wiland, J. C. Fink et al., ISLET CELL DAMAGE ASSOCIATED WITH TACROLIMUS AND CYCLOSPORINE: MORPHOLOGICAL FEATURES IN PANCREAS ALLOGRAFT BIOPSIES AND CLINICAL CORRELATION1, Transplantation, vol.68, issue.3, pp.396-402, 1999.

G. A. Knoll and R. C. Bell, Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials, BMJ, vol.318, issue.7191, pp.1104-1107, 1999.

R. S. Woodward, M. A. Schnitzler, J. Baty, J. A. Lowell, L. Lopez-rocafort et al., Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients, American Journal of Transplantation, vol.3, issue.5, pp.590-598, 2003.

F. Vincenti, Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus, Am. J. Transplant, vol.7, pp.1506-1514, 2007.

J. F. Neylan, RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1, Transplantation, vol.65, issue.4, pp.515-523, 1998.

A. Penfornis and S. Kury-paulin, Immunosuppressive drug-induced diabetes, Diabetes & Metabolism, vol.32, issue.5, pp.539-546, 2006.

J. J. Heit, Å. A. Apelqvist, X. Gu, M. M. Winslow, J. R. Neilson et al., Calcineurin/NFAT signalling regulates pancreatic ?-cell growth and function, Nature, vol.443, issue.7109, pp.345-349, 2006.

K. Tamura, Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients, Transplant International, vol.5, pp.S552-S555, 1992.

S. A. Soleimanpour, M. F. Crutchlow, A. M. Ferrari, J. C. Raum, D. N. Groff et al., Calcineurin Signaling Regulates Human Islet ?-Cell Survival, Journal of Biological Chemistry, vol.285, issue.51, pp.40050-40059, 2010.

M. A. Gelens, J. P. Van-hooff, L. Usvyat, and M. H. Christiaans, No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12 years tacrolimus exposure, Journal of Diabetes and its Complications, vol.31, issue.9, pp.1384-1388, 2017.

M. J. Pereira, J. Palming, M. Rizell, M. Aureliano, E. Carvalho et al., Cyclosporine A and Tacrolimus Reduce the Amount of GLUT4 at the Cell Surface in Human Adipocytes: Increased Endocytosis as a Potential Mechanism for the Diabetogenic Effects of Immunosuppressive Agents, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.10, pp.E1885-E1894, 2014.

A. Fuhrmann, P. Lopes, J. Sereno, J. Pedro, D. O. Espinoza et al., Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model, Biochemical Pharmacology, vol.88, issue.2, pp.216-228, 2014.

O. Johnston, C. L. Rose, A. C. Webster, and J. S. Gill, Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients, Journal of the American Society of Nephrology, vol.19, issue.7, pp.1411-1418, 2008.

E. Zahr, R. D. Molano, A. Pileggi, H. Ichii, S. S. Jose et al., Rapamycin Impairs In Vivo Proliferation of Islet Beta-Cells, Transplantation, vol.84, issue.12, pp.1576-1583, 2007.

M. Fraenkel, M. Ketzinel-gilad, Y. Ariav, O. Pappo, M. Karaca et al., mTOR Inhibition by Rapamycin Prevents -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes, Diabetes, vol.57, issue.4, pp.945-957, 2008.

M. Veroux, T. Tallarita, D. Corona, N. Sinagra, A. Giaquinta et al., Conversion to Sirolimus Therapy in Kidney Transplant Recipients with New Onset Diabetes Mellitus after Transplantation, Clinical and Developmental Immunology, vol.2013, pp.1-7, 2013.

V. Shivaswamy, B. Boerner, and J. Larsen, Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes, Endocrine Reviews, vol.37, issue.1, pp.37-61, 2015.

J. D. Johnson, Z. Ao, P. Ao, H. Li, L. Dai et al., Different Effects of FK506, Rapamycin, and Mycophenolate Mofetil on Glucose-Stimulated Insulin Release and Apoptosis in Human Islets, Cell Transplantation, vol.18, issue.8, pp.833-845, 2009.

R. Gallo, M. Natale, F. Vendrame, U. Boggi, F. Filipponi et al., In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells, Acta Diabetologica, vol.49, issue.S1, pp.123-131, 2012.

P. Masson, L. Henderson, J. R. Chapman, J. C. Craig, and A. C. Webster, Belatacept for kidney transplant recipients, Cochrane Database of Systematic Reviews, 2014.

, Discussion generale : les points essentiels a retenir, Journal de Radiologie, vol.88, issue.10, p.1297, 2007.

A. Sheu, B. Depczynski, A. J. O?sullivan, G. Luxton, and G. Mangos, The Effect of Different Glycaemic States on Renal Transplant Outcomes, Journal of Diabetes Research, vol.2016, pp.1-6, 2016.

T. Schachtner, M. Stein, and P. Reinke, Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity, Clinical Transplantation, vol.31, issue.7, p.e12986, 2017.

R. Leal, H. Pinto, A. Galvão, L. Rodrigues, L. Santos et al., Early Rehospitalization Post?Kidney Transplant Due to Infectious Complications: Can We Predict the Patients at Risk?, Transplantation Proceedings, vol.49, issue.4, pp.783-786, 2017.

J. Hjelmesæth, A. Hartmann, T. Leivestad, H. Holdaas, S. Sagedal et al., The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events, Kidney International, vol.69, issue.3, pp.588-595, 2006.

F. G. Cosio, T. E. Pesavento, S. Kim, K. Osei, M. Henry et al., Patient survival after renal transplantation: IV. Impact of post-transplant diabetes, Kidney International, vol.62, issue.4, pp.1440-1446, 2002.

A. Lindholm, D. Albrechtsen, L. Frödin, G. Tufveson, N. H. Persson et al., ISCHEMIC HEART DISEASE?MAJOR CAUSE OF DEATH AND GRAFT LOSS AFTER RENAL TRANSPLANTATION IN SCANDINAVIA, Transplantation, vol.60, issue.5, pp.451-456, 1995.

T. G. Valderhaug, J. Hjelmesæth, A. Hartmann, J. Røislien, H. A. Bergrem et al., The association of early post-transplant glucose levels with long-term mortality, Diabetologia, vol.54, issue.6, pp.1341-1349, 2011.

K. Wang, Q. Qu, S. Miao, Y. Zhang, and X. Jing, Discussion on the risk factors of developing cardiovascular diseases (CVD) after the kidney transplantation, Pak J Pharm Sci, vol.30, pp.241-246, 2017.

K. L. Lentine, D. C. Brennan, and M. A. Schnitzler, Incidence and Predictors of Myocardial Infarction after Kidney Transplantation, Journal of the American Society of Nephrology, vol.16, issue.2, pp.496-506, 2004.

T. M. Londero, L. S. Giaretta, L. P. Farenzena, R. C. Manfro, L. H. Canani et al., Microvascular Complications of Posttransplant Diabetes Mellitus in Kidney Transplant Recipients: A Longitudinal Study, The Journal of Clinical Endocrinology & Metabolism, vol.104, issue.2, pp.557-567, 2018.

M. Gregorini, V. Sepe, F. E. Pattonieri, A. Allesina, and T. Rampino, Early onset of graft glomerulopathy in a patient with post-transplant diabetes mellitus after renal transplantation: a case report, BMC Nephrology, vol.19, issue.1, p.348, 2018.

P. V. Bauer, F. A. Duca, T. M. Waise, B. A. Rasmussen, M. A. Abraham et al., Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway, Cell Metabolism, vol.27, issue.1, pp.101-117.e5, 2018.

H. Lee, Y. Lee, J. Kim, J. An, S. Lee et al., Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice, Gut Microbes, vol.9, issue.2, pp.155-165, 2018.

B. Viollet, B. Guigas, N. S. Garcia, J. Leclerc, M. Foretz et al., Cellular and molecular mechanisms of metformin: an overview, Clinical Science, vol.122, issue.6, pp.253-270, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00658070

P. Darmon, Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge me?dicamenteuse de l'hyperglyce?mie du patient diabe?tique de type 2, Médecine des Maladies Métaboliques, vol.11, pp.577-593, 2017.

B. Kurian, R. Joshi, and A. Helmuth, Effectiveness and Long-Term Safety of Thiazolidinediones and Metformin in Renal Transplant Recipients, Endocrine Practice, vol.14, issue.8, pp.979-984, 2008.

B. Alnasrallah, H. Pilmore, and P. Manley, Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study, BMJ Open, vol.7, issue.8, p.e016813, 2017.

T. Türk, F. Pietruck, S. Dolff, A. Kribben, O. E. Janssen et al., Repaglinide in the Management of New-Onset Diabetes Mellitus After Renal Transplantation, American Journal of Transplantation, vol.6, issue.4, pp.842-846, 2006.

T. S. Abdelaziz, A. Y. Ali, and M. Fatthy, Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis, Current Diabetes Reviews, vol.16, issue.6, pp.580-585, 2020.

T. S. Abdelaziz, A. Y. Ali, and M. Fatthy, Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis, Current Diabetes Reviews, vol.16, issue.6, pp.580-585, 2020.

T. A. Strom-halden, A. Asberg, K. Vik, A. Hartmann, and T. Jenssen, Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation, Nephrology Dialysis Transplantation, vol.29, issue.4, pp.926-933, 2014.

S. W. Lim, J. Z. Jin, L. Z. Jin, J. Z. Jin, and C. Li, Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation, The Korean Journal of Internal Medicine, vol.30, issue.6, pp.759-770, 2015.

T. A. Halden, E. J. Egeland, A. Åsberg, A. Hartmann, K. Midtvedt et al., GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes, Diabetes Care, vol.39, issue.4, pp.617-624, 2016.

S. Verma, N. R. Poulter, D. L. Bhatt, S. C. Bain, J. B. Buse et al., Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke, Circulation, vol.138, issue.25, pp.2884-2894, 2018.

H. C. Gerstein, Review for "Efficacy and safety of empagliflozin as add?on to insulin in Japanese patients with type 2 diabetes: a randomised, double?blind, placebo?controlled trial", Lancet, vol.394, pp.121-130, 2019.

D. H. Van-raalte, R. E. Van-genugten, M. M. Linssen, D. M. Ouwens, and M. Diamant, Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans, Diabetes Care, vol.34, issue.2, pp.412-417, 2011.

Y. Li, W. Xu, Z. Liao, B. Yao, X. Chen et al., Induction of Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Is Associated With Improvement of -Cell Function, Diabetes Care, vol.27, issue.11, pp.2597-2602, 2004.

C. K. Kramer, B. Zinman, and R. Retnakaran, Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis, The Lancet Diabetes & Endocrinology, vol.1, issue.1, pp.28-34, 2013.

L. Cheng, M. Xu, X. Lin, J. Tang, Y. Qi et al., The intriguing effects of time to glycemic goal in newly diagnosed type 2 diabetes after short-term intensive insulin therapy, Endocrine Journal, vol.63, issue.8, pp.739-746, 2016.

T. Vanhove, Q. Remijsen, D. Kuypers, and P. Gillard, Drug?drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus, Transplantation Reviews, vol.31, issue.2, pp.69-77, 2017.

M. Gertz, C. M. Cartwright, M. J. Hobbs, K. E. Kenworthy, M. Rowland et al., Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential, Pharmaceutical Research, vol.30, issue.3, pp.761-780, 2012.

Y. Shitara, Clinical Importance of OATP1B1 and OATP1B3 in Drug­Drug Interactions, Drug Metabolism and Pharmacokinetics, vol.26, issue.3, pp.220-227, 2011.

J. Bae, M. J. Lee, E. Y. Choe, C. H. Jung, H. J. Wang et al., Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study, Endocrinology and Metabolism, vol.31, issue.1, p.161, 2016.

B. H. Kim, Differentiated Thyroid Cancer in Asians, Endocrinology and Metabolism, vol.31, issue.1, p.62, 2016.

B. P. Boerner, C. D. Miles, and V. Shivaswamy, Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation, International Journal of Endocrinology, vol.2014, pp.1-9, 2014.

J. Werzowa, M. Hecking, M. Haidinger, F. Lechner, D. Döller et al., Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation, Transplantation Journal, vol.95, issue.3, pp.456-462, 2013.

M. Haidinger, J. Werzowa, M. Hecking, M. Antlanger, G. Stemer et al., Efficacy and Safety of Vildagliptin in New-Onset Diabetes After Kidney Transplantation-A Randomized, Double-Blind, Placebo-Controlled Trial, American Journal of Transplantation, vol.14, issue.1, pp.115-123, 2013.

E. Gaiffe, T. Crepin, J. Bamoulid, C. Courivaud, M. Büchler et al., PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study, Trials, vol.20, issue.1, p.375, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02173487

B. Cariou, C. Bernard, and D. Cantarovich, Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series, Diabetes & Metabolism, vol.41, issue.3, pp.252-257, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02147105

J. Liou, Y. Liu, and C. Chen, Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study, Transplantation Proceedings, vol.50, issue.8, pp.2502-2505, 2018.

N. R. Pinelli, A. Patel, and F. D. Salinitri, Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series, Diabetes Care, vol.36, issue.10, pp.e171-e172, 2013.

P. Singh, T. E. Pesavento, K. Washburn, D. Walsh, and S. Meng, Largest single?centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients, Diabetes, Obesity and Metabolism, vol.21, issue.4, pp.1061-1065, 2019.

T. A. Halden, K. E. Kvitne, K. Midtvedt, L. Rajakumar, I. Robertsen et al., Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus, Diabetes Care, vol.42, issue.6, pp.1067-1074, 2019.

S. C. Ramirez, J. Maaske, Y. Kim, V. Neagu, S. Delange et al., The Association Between Glycemic Control and Clinical Outcomes After Kidney Transplantation, Endocrine Practice, vol.20, issue.9, pp.894-900, 2014.

K. L. Hermayer, M. F. Egidi, N. J. Finch, P. Baliga, A. Lin et al., A Randomized Controlled Trial to Evaluate the Effect of Glycemic Control on Renal Transplantation Outcomes, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.12, pp.4399-4406, 2012.

C. Conte and A. Secchi, Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention, Acta Diabetologica, vol.55, issue.8, pp.763-779, 2018.

K. Benomar, S. Espiard, C. Vahe, K. Le-mapihan, A. Jannin et al., Post-transplantation diabetes: Treatment à la carte ?, Diabetes & Metabolism, vol.43, issue.4, pp.378-381, 2017.

, Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, American Journal of Transplantation, vol.9, pp.S1-S155, 2009.

D. Sinning and U. Landmesser, ESC-Leitlinien 2016 ? Dyslipidämien, Herz, vol.41, issue.8, pp.671-676, 2016.

F. Verbeke, E. Lindley, L. Van-bortel, R. Vanholder, G. London et al., A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application, Nephrology Dialysis Transplantation, vol.29, issue.3, pp.490-496, 2013.

H. A. Bergrem, T. G. Valderhaug, A. Hartmann, J. Hjelmesæth, T. Leivestad et al., Undiagnosed Diabetes in Kidney Transplant Candidates: A Case-Finding Strategy, Clinical Journal of the American Society of Nephrology, vol.5, issue.4, pp.616-622, 2010.

M. Guthoff, D. Vosseler, J. Langanke, S. Nadalin, A. Königsrainer et al., Diabetes Mellitus and Prediabetes on Kidney Transplant Waiting List- Prevalence, Metabolic Phenotyping and Risk Stratification Approach, PLOS ONE, vol.10, issue.9, p.e0134971, 2015.

, Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study, The Lancet Diabetes & Endocrinology, vol.3, issue.11, pp.866-875, 2015.

A. Sharif, R. Moore, and K. Baboolal, Influence of Lifestyle Modification in Renal Transplant Recipients With Postprandial Hyperglycemia, Transplantation, vol.85, issue.3, pp.353-358, 2008.

M. Hecking, M. Haidinger, D. Döller, J. Werzowa, A. Tura et al., Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation, Journal of the American Society of Nephrology, vol.23, issue.4, pp.739-749, 2012.

F. Batista, I. Auyanet, J. Torregrosa, and F. Oppenheimer, Long-Term Follow-up After Conversion From Tacrolimus to Cyclosporin in Renal Transplant Patients With New-Onset Diabetes Mellitus After Transplantation, Transplantation Proceedings, vol.44, issue.9, pp.2582-2584, 2012.

E. David-neto, F. C. Lemos, L. M. Fadel, F. Agena, M. Y. Sato et al., The Dynamics of Glucose Metabolism Under Calcineurin Inhibitors in the First Year After Renal Transplantation in Nonobese Patients, Transplantation, vol.84, issue.1, pp.50-55, 2007.

F. Kälble, J. Seckinger, M. Schaier, C. Morath, V. Schwenger et al., Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients, Clinical Transplantation, vol.31, issue.8, p.e13024, 2017.

D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher et al., Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, vol.28, issue.7, pp.412-419, 1985.

K. J. Mather, A. E. Hunt, H. O. Steinberg, G. Paradisi, G. Hook et al., Repeatability Characteristics of Simple Indices of Insulin Resistance: Implications for Research Applications, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.11, pp.5457-5464, 2001.

P. J. Lefebvre and A. S. Luyckx, The breakfast tolerance test: a return to physiology, Diabete Metab, vol.2, pp.15-19, 1976.

M. Guthoff, R. Wagner, K. Weichbrodt, S. Nadalin, A. Königsrainer et al., Dynamics of Glucose Metabolism After Kidney Transplantation, Kidney and Blood Pressure Research, vol.42, issue.3, pp.598-607, 2017.

F. Tillmann, L. C. Rump, and I. Quack, HbA1c levels at 90 days after renal transplantation in non-diabetic recipients predict de novo pre-diabetes and diabetes at 1 and 3 years after transplantation, International Urology and Nephrology, vol.50, issue.8, pp.1529-1534, 2018.

C. Courivaud, M. Ladrière, O. Toupance, S. Caillard, B. H. De-ligny et al., Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation, Clinical Transplantation, vol.25, issue.5, pp.794-799, 2010.

F. Terrec, T. Jouve, H. Naciri-bennani, P. Benhamou, P. Malvezzi et al., Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters, Transplantation Direct, vol.6, issue.1, p.e517, 2020.

D. D. De-lucena, J. R. De-sá, J. O. Medina-pestana, and É. B. Rangel, Modifiable Variables Are Major Risk Factors for Posttransplant Diabetes Mellitus in a Time-Dependent Manner in Kidney Transplant: An Observational Cohort Study, Journal of Diabetes Research, vol.2020, pp.1-10, 2020.

J. Bons, L. Jeandel, D. Hulot, L. Moreau-grange, M. Bladziak et al., P203 Mesure des concentrations plasmatiques du neuropeptide orexigène 26RFa au cours d?un repas calibré : influence du diabète, Diabetes & Metabolism, vol.41, p.A84, 2015.

, Collaboration avec les pairs chez les enseignants dans le groupe expérimental, 2020.

A. Grimaldi and A. Hartemann-heurtier, Hyperglycémie à jeun et intolérance aux hydrates de carbone, Guide pratique du diabète, pp.8-10, 2009.

. Coremans, L'année de l'ancienne Belgique. Mémoire sur les saisons, les mois, les semaines, les jours, les fêtes dans les temps antérieurs à l'introduction du christianisme en Belgique, avec l'indication et l'explication de différentes dates qui se trouvent dans les documents du moyen âge, et qui en partie sont encore usitées de nos jours, Compte-rendu des séances de la commission royale d'histoire, vol.7, issue.7, pp.11-192, 1844.

, Les modalités de traitement sont très différentes entre le secteur spécialisé des soins de santé mentale et le secteur des soins primaires, L'objectif principal de ce travail est d'e?valuer les anomalies glyce?miques pre?coces, à 3 mois et à 6 mois au sein d'une population greffe?e re?nale non diabe?tique du CHU de Rouen, p.3, 2012.

, Les jeunes qui sont entrés sur le marché du travail pendant la crise ont connu une croissance inférieure de l'emploi et des revenus, Les facteurs de risque ressortis pour le PTDM à 6 mois sont l'âge > 40 ans (p = 0,009) et la GAJ à J7, p.0, 2017.